Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Infergen + Ribavirin in HCV Non-Responders
NCT00266318Phase 4Completed
- Sponsor
- Mount Sinai Beth Israel
- Start
- Dec 2005
- Primary completion
- May 2007
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Peginterferon alfacon-1 in hepatitis C (HCV), sponsored by Mount Sinai Beth Israel. Primary endpoint: Assessment of safety and tolerability at 48 weeks. Started Dec 2005; status: completed.
02
Drugs
Peginterferon alfacon-1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00266318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266318.